7:01 am ISIS Pharm reports interim results from ISIS-SMN Rx multiple dose study in children with spinal muscular atrophy; average increase of 3.7 points observed in muscle function score in SMA children treated with 9 mg of ISIS-SMN Rx; on

7:01 am ISIS Pharm reports interim results from ISIS-SMN Rx multiple dose study in children with spinal muscular atrophy; average increase of 3.7 points observed in muscle function score in SMA children treated with 9 mg of ISIS-SMN Rx; on

more

View todays social media effects on ISIS

View the latest stocks trending across Twitter. Click to view dashboard

See who Isis is hiring next, click here to view

Share this post